Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
株式のランク
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
株価
$4.87
時価総額
$4.36B
変化（1日）
-5.47%
変化（1年）
-15.62%
国
CN
取引 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
カテゴリー
Healthcare
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（688336）の配当履歴
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（証券コード：688336）は合計で5回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$0.63
配当利回り（TTM）：0.0149
すべての配当の合計（株式分割調整済み）は：$0.63
配当利回り（TTM）：0.0149
2024から2026までのSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（688336）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $0.45 | 265.85% |
| 2025 | $0.123 | 114.66% |
| 2024 | $0.0573 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $0.6525 | 265.75% |
| 2025 | $0.1784 | 114.94% |
| 2024 | $0.083 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 67.00% |
AU
|
|
| 30.00% |
BE
|
|
| 0.00% |
NL
|
